The 7 most recent market catalysts affecting $SLS, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 11, 2026
Market Technicals
Neutral
Impact 55
10 Health Care Stocks With Whale Alerts In Today’s Session
The filing details 'whale alerts' in the options market for ten healthcare stocks, indicating large, potentially informed trades. This matters because significant options activity …
Sep 2, 2026
Corporate Catalyst
Neutral
Impact 55
SELLAS Life Sciences Says Three Abstracts Evaluating SLS009, Potent, Selective CDK9 Inhibitor, In Preclinical Models Of PDAC Accepted For Poster Presentation At AACR Conference On Pancreatic Cancer
SELLAS Life Sciences announced the acceptance of three abstracts for poster presentation at the AACR Conference on Pancreatic Cancer. These abstracts detail preclinical activity of…
Aug 31, 2026
Corporate Catalyst
Bearish
Impact 85
SLS Stock Looks Like a $3 Billion Biotech Winner—This Short Seller Says the Market Has It Dangerously Wrong: 'Most Expensive Coin Flip' (UPDATED)
BMF Capital's short report on SELLAS Life Sciences (SLS) is a significant event for the company and its investors. The report directly challenges the validity of the ongoing Phase …
Aug 27, 2026
Corporate Catalyst
Bullish
Impact 75
When Revolution Medicines' FDA Win Lifts Other Boats: SELLAS Life Sciences Stock Surges
The core event is the FDA approval of Revolution Medicines' Rasonque for metastatic pancreatic adenocarcinoma. This approval is a direct positive catalyst for RVMD, validating a ne…
Aug 27, 2026
Corporate Catalyst
Neutral
Impact 75
SL Science Highlights New FDA Drug Master File For GDT Cell-Derived Exosomes
The filing of an FDA Drug Master File (DMF) is a crucial step in the drug development process, streamlining regulatory review for future products utilizing the GDT Cell-Derived Exo…
Aug 21, 2026
Market Technicals
Neutral
Impact 65
10 Health Care Stocks Whale Activity In Today’s Session
This filing is a 'whale alert' indicating large-scale options trading activity in several health care stocks. Such activity, particularly 'sweeps' (orders split across multiple exc…
Aug 11, 2026
Corporate Catalyst
Bearish
Impact 92
SELLAS Life Sciences Gr Q2 EPS $(0.05) Misses $(0.04) Estimate
SELLAS Life Sciences Group (SLS) announced Q2 earnings per share (EPS) of $(0.05), which significantly missed the consensus analyst estimate of $(0.04). This 25% miss, coupled with…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.